Waldron Private Wealth’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

Waldron Private Wealth’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-3,957	Closed	-$247K	–	130
2015 Q1	$247K	Sell	3,957 -1,191	-23%	-$69.2K	0.1%	94
2014 Q4	$296K	Sell	5,148 -40	-0.8%	-$2.23K	0.12%	72
2014 Q3	$278K	Sell	5,188 -822	-14%	-$43.5K	0.13%	68
2014 Q2	$315K	Sell	6,010 -222	-4%	-$11.3K	0.15%	70
2014 Q1	$329K	Buy	6,232 +409	+7%	+$18.9K	0.16%	62
2013 Q4	$233K	Buy	+5,823	New	+$229K	0.11%	94

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Lazard Asset Management New York $66.1B AUM 33.53% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return

BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $33B AUM 40.62% 1-Year Est. Return

Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return

PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return

Waldron Private Wealth's TEVA Position: Q2 2015 in Review

Waldron Private Wealth sold out of Teva Pharmaceutical Industries Limited (TEVA) in Q2 2015, closing a stake of 3,957 shares — an estimated $247K sold.

Waldron Private Wealth first reported a position in TEVA in Q4 2013 and held it in 6 quarters. The position peaked at $329K in Q1 2014. 819 funds tracked by Wall St. Rank hold TEVA as of Q2 2015.

Waldron Private Wealth reported no remaining Teva Pharmaceutical Industries Limited position as of Q2 2015 after selling out during the quarter.
Waldron Private Wealth sold 3,957 Teva Pharmaceutical Industries Limited shares in Q2 2015, an estimated $247K.
Waldron Private Wealth first reported a position in Teva Pharmaceutical Industries Limited in Q4 2013 and held it in 6 quarters.
Waldron Private Wealth's Teva Pharmaceutical Industries Limited position peaked at $329K in Q1 2014.
819 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q2 2015.

Based on Waldron Private Wealth's 13F filing for Q2 2015, filed 12 Aug 2015.